Research programme: herpes simplex vaccine - Immune Design

Drug Profile

Research programme: herpes simplex vaccine - Immune Design

Alternative Names: G103; Herpes symplex virus 2 vaccine - Immune Design; HSV therapeutic vaccine - Immune Design; HSV2 vaccine + GLA - Immune Design; IDC-G103

Latest Information Update: 17 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Design
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Herpes simplex virus type 2 infections

Most Recent Events

  • 17 Aug 2016 IDC G103 is still in preclinical development for Herpes simplex virus type-2 infections in USA (Immune Design pipeline, August 2016; Immune Design 10-Q, April 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections in USA
  • 16 Oct 2014 Sanofi Pasteur and Immune Design Corporation enter into a broad collaboration to develop HSV immunotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top